Ethos Laboratories Expands Infectious Disease Offerings

NEWPORT, KENTUCKY?(November 7, 2022) – Ethos Laboratories, a high-complexity laboratory, today announced the expansion of its infectious disease offerings into Urinary Tract Infection (UTI) and Sexually Transmitted Infection (STI) tests enhanced by Antibiotic Resistance Testing. These new assays complement the company's experience in polymerase chain reaction (PCR) methods to provide a broader range of offerings under the company's new Infectious Disease Intelligence portfolio.

"This launch represents another significant milestone at Ethos Laboratories," said Todd Hall, Vice President of Sales and Marketing. "Today we expand our capabilities to better achieve our purpose of helping more people. We leverage our experience and expertise over the past several years in PCR testing to deliver UTI and STI testing that's more sensitive and provides a significantly faster result than traditional culture methods. And providers can utilize our Antibiotic Resistance Testing to help select the most effective drug in the treatment of these infections. We are excited about the impacts this will provide on patient care and in our evolution to become a more significant contributor in the area of personalized medicine."

Urinary Tract Infections are the most common of all bacterial infections, with a lifetime incidence of 50 to 60 percent in adult women. One in five people in the U.S. have a sexually transmitted infection. For both tests, the PCR methods utilized by Ethos have a significantly improved sensitivity compared to traditional bacterial culture testing. Speed of result is also important. Results from PCR testing can be obtained in 24 hours from receipt of the sample in the lab compared to three to seven days for a full result from bacterial culture methods. A delayed result, improper diagnosis, or ineffective treatment plan can cause chronic infections, kidney damage, sepsis, chronic discomfort, mental health issues, and other conditions. And one in three urinary tract infections shows resistance to antibiotics. Ethos' Antibiotic Resistance Testing provides a measurement of the susceptibility of bacteria to antibiotics that helps healthcare providers prescribe the appropriate treatment the first time.

About Ethos Laboratories

Ethos’ commitment to continued innovation is rooted in the company’s passion for cutting-edge laboratory science and our desire to invest in research and development with the goal of helping more people. We are a CAP-accredited, CLIA-certified, high-complexity laboratory that specializes in pain-management and infectious-disease testing. Our diagnostic offerings help assess patient health, allowing providers and patients to make informed clinical decisions in patient care. Ethos Laboratories will continue to innovate with the mission of improving our understanding of chronic disease and enhancing the lives of patients who are impacted by such conditions. For more information, visit www.ethos-labs.com.

Media Contact:?Colleen Kirkpatrick, Director of Human Resources and Compliance ([email protected])

Sales Contact: Todd Hall, Vice President of Sales & Marketing ([email protected])